Emerging pharmacotherapy of tinnitus
One in ten adults has clinically significant subjective tinnitus, and for one in hundred, tinnitus severely affects their quality of life. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the mar...
Guardado en:
| Publicado: |
2011
|
|---|---|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14728214_v16_n4_p603_Langguth http://hdl.handle.net/20.500.12110/paper_14728214_v16_n4_p603_Langguth |
| Aporte de: |
| id |
paper:paper_14728214_v16_n4_p603_Langguth |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_14728214_v16_n4_p603_Langguth2023-06-08T16:17:32Z Emerging pharmacotherapy of tinnitus Animal models Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception Randomized clinical trials 2,3 dihydro 5 methyl 3 (morpholinomethyl) 6 (1 naphthoyl)pyrrolo[1,2,3 de][1,4]benzoxazine 4 (1,1 dimethylheptyl) 1',2',3',4',5',6' hexahydro 2,3' dihydroxy 6' (3 hydroxypropyl)biphenyl 4 aminobutyric acid receptor stimulating agent am 101 AMPA receptor antagonist anticonvulsive agent antidepressant agent antidiuretic agent antihistaminic agent anxiolytic agent bcg 492a calcium channel blocking agent cholinergic receptor blocking agent cilostazol clonazepam dexamethasone flindokalner flupentixol gabapentin melitracen n methyl dextro aspartic acid receptor blocking agent neramexane neuroleptic agent oto 104 paroxetine placebo sodium channel blocking agent taurine unclassified drug unindexed drug vestipitant vigabatrin acute disease adjuvant therapy anxiety disorder auditory nervous system chronic disease clinical trial (topic) controlled clinical trial (topic) depression drug approval drug industry drug targeting epilepsy food and drug administration GABAergic transmission human migraine nerve cell plasticity neurochemistry neuropathic pain nonhuman pathophysiology phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) quality of life randomized controlled trial (topic) review sleep disorder tinnitus Animals Clinical Trials as Topic Disease Models, Animal Drug Evaluation, Preclinical Drugs, Investigational Humans Tinnitus Treatment Outcome One in ten adults has clinically significant subjective tinnitus, and for one in hundred, tinnitus severely affects their quality of life. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the market. Even a drug that produces a small but significant effect would have a huge therapeutic impact. In the last few years, there have been significant advances in i) the understanding of the pathophysiology of the different forms of tinnitus, ii) the establishment of valid animal models and iii) the development of clinical trial methodology. A glimpse of hope is appearing in the horizon as an increasing number of pharmaceutical industries now have compounds targeting tinnitus in their pipeline. © 2011 Informa UK, Ltd. 2011 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14728214_v16_n4_p603_Langguth http://hdl.handle.net/20.500.12110/paper_14728214_v16_n4_p603_Langguth |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Animal models Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception Randomized clinical trials 2,3 dihydro 5 methyl 3 (morpholinomethyl) 6 (1 naphthoyl)pyrrolo[1,2,3 de][1,4]benzoxazine 4 (1,1 dimethylheptyl) 1',2',3',4',5',6' hexahydro 2,3' dihydroxy 6' (3 hydroxypropyl)biphenyl 4 aminobutyric acid receptor stimulating agent am 101 AMPA receptor antagonist anticonvulsive agent antidepressant agent antidiuretic agent antihistaminic agent anxiolytic agent bcg 492a calcium channel blocking agent cholinergic receptor blocking agent cilostazol clonazepam dexamethasone flindokalner flupentixol gabapentin melitracen n methyl dextro aspartic acid receptor blocking agent neramexane neuroleptic agent oto 104 paroxetine placebo sodium channel blocking agent taurine unclassified drug unindexed drug vestipitant vigabatrin acute disease adjuvant therapy anxiety disorder auditory nervous system chronic disease clinical trial (topic) controlled clinical trial (topic) depression drug approval drug industry drug targeting epilepsy food and drug administration GABAergic transmission human migraine nerve cell plasticity neurochemistry neuropathic pain nonhuman pathophysiology phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) quality of life randomized controlled trial (topic) review sleep disorder tinnitus Animals Clinical Trials as Topic Disease Models, Animal Drug Evaluation, Preclinical Drugs, Investigational Humans Tinnitus Treatment Outcome |
| spellingShingle |
Animal models Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception Randomized clinical trials 2,3 dihydro 5 methyl 3 (morpholinomethyl) 6 (1 naphthoyl)pyrrolo[1,2,3 de][1,4]benzoxazine 4 (1,1 dimethylheptyl) 1',2',3',4',5',6' hexahydro 2,3' dihydroxy 6' (3 hydroxypropyl)biphenyl 4 aminobutyric acid receptor stimulating agent am 101 AMPA receptor antagonist anticonvulsive agent antidepressant agent antidiuretic agent antihistaminic agent anxiolytic agent bcg 492a calcium channel blocking agent cholinergic receptor blocking agent cilostazol clonazepam dexamethasone flindokalner flupentixol gabapentin melitracen n methyl dextro aspartic acid receptor blocking agent neramexane neuroleptic agent oto 104 paroxetine placebo sodium channel blocking agent taurine unclassified drug unindexed drug vestipitant vigabatrin acute disease adjuvant therapy anxiety disorder auditory nervous system chronic disease clinical trial (topic) controlled clinical trial (topic) depression drug approval drug industry drug targeting epilepsy food and drug administration GABAergic transmission human migraine nerve cell plasticity neurochemistry neuropathic pain nonhuman pathophysiology phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) quality of life randomized controlled trial (topic) review sleep disorder tinnitus Animals Clinical Trials as Topic Disease Models, Animal Drug Evaluation, Preclinical Drugs, Investigational Humans Tinnitus Treatment Outcome Emerging pharmacotherapy of tinnitus |
| topic_facet |
Animal models Anticonvulsants Antidepressants Anxiolytics Auditory system GABA Glutamate Hearing Inner ear NMDA Pain Phantom perception Randomized clinical trials 2,3 dihydro 5 methyl 3 (morpholinomethyl) 6 (1 naphthoyl)pyrrolo[1,2,3 de][1,4]benzoxazine 4 (1,1 dimethylheptyl) 1',2',3',4',5',6' hexahydro 2,3' dihydroxy 6' (3 hydroxypropyl)biphenyl 4 aminobutyric acid receptor stimulating agent am 101 AMPA receptor antagonist anticonvulsive agent antidepressant agent antidiuretic agent antihistaminic agent anxiolytic agent bcg 492a calcium channel blocking agent cholinergic receptor blocking agent cilostazol clonazepam dexamethasone flindokalner flupentixol gabapentin melitracen n methyl dextro aspartic acid receptor blocking agent neramexane neuroleptic agent oto 104 paroxetine placebo sodium channel blocking agent taurine unclassified drug unindexed drug vestipitant vigabatrin acute disease adjuvant therapy anxiety disorder auditory nervous system chronic disease clinical trial (topic) controlled clinical trial (topic) depression drug approval drug industry drug targeting epilepsy food and drug administration GABAergic transmission human migraine nerve cell plasticity neurochemistry neuropathic pain nonhuman pathophysiology phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) quality of life randomized controlled trial (topic) review sleep disorder tinnitus Animals Clinical Trials as Topic Disease Models, Animal Drug Evaluation, Preclinical Drugs, Investigational Humans Tinnitus Treatment Outcome |
| description |
One in ten adults has clinically significant subjective tinnitus, and for one in hundred, tinnitus severely affects their quality of life. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the market. Even a drug that produces a small but significant effect would have a huge therapeutic impact. In the last few years, there have been significant advances in i) the understanding of the pathophysiology of the different forms of tinnitus, ii) the establishment of valid animal models and iii) the development of clinical trial methodology. A glimpse of hope is appearing in the horizon as an increasing number of pharmaceutical industries now have compounds targeting tinnitus in their pipeline. © 2011 Informa UK, Ltd. |
| title |
Emerging pharmacotherapy of tinnitus |
| title_short |
Emerging pharmacotherapy of tinnitus |
| title_full |
Emerging pharmacotherapy of tinnitus |
| title_fullStr |
Emerging pharmacotherapy of tinnitus |
| title_full_unstemmed |
Emerging pharmacotherapy of tinnitus |
| title_sort |
emerging pharmacotherapy of tinnitus |
| publishDate |
2011 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_14728214_v16_n4_p603_Langguth http://hdl.handle.net/20.500.12110/paper_14728214_v16_n4_p603_Langguth |
| _version_ |
1768542379691737088 |